Exploiting potential molecular compounds for treating testicular seminoma by targeting immune related genes
The signature initially constructed based on immune-related genes shows promise for predicting outcomes and assessing the efficacy of immunotherapy in seminoma patients. Rutin, ICG-001, and Doxorubicin have demonstrated potential to target these signature genes and inhibit tumor cell viability.
Authors
- Haowei He (ORCID: https://orcid.org/0000-0002-0358-4983)
- Bo Fang (ORCID: https://orcid.org/0000-0002-1540-6818)
- Bianjiang Liu (ORCID: https://orcid.org/0000-0002-4705-6445)
- Hao Tang (ORCID: https://orcid.org/0000-0002-2077-1246)
- Jing Zhang (ORCID: https://orcid.org/0000-0001-8549-3286)
- Jingping Ge (ORCID: https://orcid.org/0000-0002-7052-7903)
- Xue‐Jun Shang (ORCID: https://orcid.org/0000-0002-9402-1464)
- Xiaodie Zhou
- Feng Xu
- Yankang Cui
Institutions
- Nanjing General Hospital of Nanjing Military Command (CN)
- Nanjing Product Quality Supervision and Inspection Institute (CN)
- Nanjing Medical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Cell Communication and Signaling
- Published
- 2024-11-21
- DOI
- https://doi.org/10.1186/s12964-024-01927-w
- Citations
- 2
- Primary Topic
- Testicular diseases and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.15
Funders
- National Natural Science Foundation of China